NasdaqGS:ALVR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has AlloVir's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALVR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: Insufficient data to determine ALVR's volatility change over the past year.


Market Performance


7 Day Return

4.6%

ALVR

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

n/a

ALVR

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: Insufficient data to determine how ALVR performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ALVR performed against the US Market.


Shareholder returns

ALVRIndustryMarket
7 Day4.6%3.5%-1.0%
30 Day2.5%4.5%2.2%
90 Day59.9%19.2%11.5%
1 Yearn/a39.0%36.8%22.3%19.6%
3 Yearn/a30.5%23.6%45.3%35.7%
5 Yearn/a43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is AlloVir's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AlloVir undervalued compared to its fair value and its price relative to the market?

7.41x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ALVR ($44.93) is trading above our estimate of fair value ($13.42)

Significantly Below Fair Value: ALVR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALVR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALVR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALVR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALVR is overvalued based on its PB Ratio (7.4x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is AlloVir forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-9.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALVR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALVR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALVR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALVR's revenue (64.9% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: ALVR's revenue (64.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALVR is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has AlloVir performed over the past 5 years?

-169.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ALVR is currently unprofitable.

Growing Profit Margin: ALVR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ALVR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ALVR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALVR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: ALVR has a negative Return on Equity (-14.26%), as it is currently unprofitable.


Next Steps

Financial Health

How is AlloVir's financial position?


Financial Position Analysis

Short Term Liabilities: ALVR's short term assets ($383.9M) exceed its short term liabilities ($13.5M).

Long Term Liabilities: ALVR's short term assets ($383.9M) exceed its long term liabilities ($6.3M).


Debt to Equity History and Analysis

Debt Level: ALVR is debt free.

Reducing Debt: ALVR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALVR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALVR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is AlloVir current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALVR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALVR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALVR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALVR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALVR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

David Hallal (54 yo)

2.33yrs

Tenure

US$3,565,110

Compensation

Mr. David L. Hallal serves as Lead Independent Director of Seer Biosciences, Inc. since September 2020. Mr. Hallal serves as a Director of Seer Biosciences, Inc. since February 2018. Mr. Hallal is Chairman...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD3.57M) is about average for companies of similar size in the US market ($USD5.00M).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
David Hallal
Chairman & CEO2.33yrsUS$3.57m5.2%
$ 144.0m
Vikas Sinha
Presidentno dataUS$1.63m1.31%
$ 36.2m
Agustin Melian
Chief Medical Officer & Head of Global Medical Sciences1.75yrsUS$2.18m0.86%
$ 23.9m
Brett Hagen
Chief Accounting Officer2yrsno data0.088%
$ 2.4m
Ann Leen
Chief Scientific Officer8yrsno data4.05%
$ 112.2m
Edward Miller
General Counsel2yrsno data0.59%
$ 16.4m
Jeroen Van Beek
Chief Commercial Officer2yrsno data0.85%
$ 23.6m
Ugo Perlingieri
Head & GM of Europe and Middle East Operations0.75yrno datano data
Ercem Atillasoy
Chief Regulatory & Safety Officer0.50yrno data0.13%
$ 3.5m
Dana Alexander
Senior Vice President of Technical Operations1yrno datano data

2.0yrs

Average Tenure

55yo

Average Age

Experienced Management: ALVR's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Hallal
Chairman & CEO2.33yrsUS$3.57m5.2%
$ 144.0m
Vikas Sinha
Presidentno dataUS$1.63m1.31%
$ 36.2m
Ansbert Gadicke
Independent Non-Executive Director2.33yrsUS$130.90k0.049%
$ 1.4m
Malcolm Brenner
Independent Non-Executive Director9yrsUS$125.90k0.049%
$ 1.4m
Jeffrey Bornstein
Independent Non-Executive Director0.50yrno data0.082%
$ 2.3m
Morana Jovan-Embiricos
Independent Non-Executive Director1.67yrsUS$117.15k8.09%
$ 224.1m
John Wilson
Independent Non-Executive Director3yrsUS$130.90k5.21%
$ 144.4m
Diana Brainard
Independent Non-Executive Director0.50yrno data0.010%
$ 283.1k
Juan Vera
Non-Executive Directorno dataUS$240.90k4%
$ 110.8m

2.3yrs

Average Tenure

54yo

Average Age

Experienced Board: ALVR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: ALVR only recently listed within the past 12 months.


Top Shareholders

Company Information

AlloVir, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AlloVir, Inc.
  • Ticker: ALVR
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.770b
  • Shares outstanding: 61.66m
  • Website: https://www.allovir.com

Number of Employees


Location

  • AlloVir, Inc.
  • 139 Main Street
  • Suite 500
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALVRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2020

Biography

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 00:57
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.